Autologous stem cell transplantation in patients who object to a blood transfusion: contribution of new pharmacological haematopoiesis support. (يفتح نافذة جديدة)

Al-Nawakil C, Quarre MC, Heshmati F, Deau B, Park S, Dreyfus F, Bouscary D, Tamburini J.

Source‎: Br J Haematol 2013;161(5):738-40.

مفهرسة‎: PubMed 23480574

DOI‎: 10.1111/bjh.12284

https://www.ncbi.nlm.nih.gov/pubmed/23480574 (يفتح نافذة جديدة)

A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. (يفتح نافذة جديدة)

Al-Samkari H, Parnes AD, Goodarzi K, Weitzman JI, Connors JM, Kuter DJ

Source‎: Haematologica 2021;106(4):1148-57.

مفهرسة‎: PubMed 32499239

DOI‎: 10.3324/haematol.2020.251900

https://www.ncbi.nlm.nih.gov/pubmed/32499239 (يفتح نافذة جديدة)

The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. (يفتح نافذة جديدة)

Aribi A, Kantarjian H, Koller C, Thomas D, Faderl S, Garcia-Manero G, Cortes J.

Source‎: Cancer 2008;113(6):1338-43.

مفهرسة‎: PubMed 18629842

DOI‎: 10.1002/cncr.23718

https://www.ncbi.nlm.nih.gov/pubmed/18629842 (يفتح نافذة جديدة)

Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia. (يفتح نافذة جديدة)

Berthelot-Richer M, Boilard B, Morin A, Bolduc B, Beauregard P, Kotb R.

Source‎: Transfusion 2012;52(4):739-41.

مفهرسة‎: PubMed 22082044

DOI‎: 10.1111/j.1537-2995.2011.03382.x

https://www.ncbi.nlm.nih.gov/pubmed/22082044 (يفتح نافذة جديدة)

The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes. (يفتح نافذة جديدة)

Bhatia M, Davenport V, Cairo MS.

Source‎: Leuk Lymphoma 2007;48(1):9-15.

مفهرسة‎: PubMed 17325843

DOI‎: 10.1080/10428190600909115

https://www.ncbi.nlm.nih.gov/pubmed/17325843 (يفتح نافذة جديدة)

Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. (يفتح نافذة جديدة)

Chawla SP, Staddon A, Hendifar A, Messam CA, Patwardhan R, Kamel YM.

Source‎: BMC Cancer 2013;13:121.

مفهرسة‎: PubMed 23497336

DOI‎: 10.1186/1471-2407-13-121

https://www.ncbi.nlm.nih.gov/pubmed/23497336 (يفتح نافذة جديدة)

Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma. (يفتح نافذة جديدة)

Demeter J, Istenes I, Fodor A, Paksi M, Dombi P, Valasinyószki E, Csomor J, Matolcsy A, Nagy ZG.

Source‎: Pathol Oncol Res 2011;17(1):141-3.

مفهرسة‎: PubMed 20628840

DOI‎: 10.1007/s12253-010-9276-4

https://www.ncbi.nlm.nih.gov/pubmed/20628840 (يفتح نافذة جديدة)

Eltrombopag for radiation-induced thrombocytopenia in a glioblastoma patient. (يفتح نافذة جديدة)

Duic JP, Grewal J, McConie K, Staszewski H, Haas J, Kesari S.

Source‎: J Neurooncol 2012;106(2):427-9.

مفهرسة‎: PubMed 21833801

DOI‎: 10.1007/s11060-011-0675-5

https://www.ncbi.nlm.nih.gov/pubmed/21833801 (يفتح نافذة جديدة)

Recombinant human interleukin 11 and bacterial infection in patients with haematological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial. (يفتح نافذة جديدة)

Ellis M, Zwaan F, Hedström U, Poynton C, Kristensen J, Jumaa P, Wassell J, al-Ramadi B.

Source‎: Lancet 2003;361(9354):275-80.

مفهرسة‎: PubMed 12559860

https://www.ncbi.nlm.nih.gov/pubmed/12559860 (يفتح نافذة جديدة)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (يفتح نافذة جديدة)

Ford PA, Grant SJ, Mick R, Keck G.

Source‎: J Clin Oncol 2015;33(15):1674-9.

مفهرسة‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (يفتح نافذة جديدة)

Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors. (يفتح نافذة جديدة)

Gao Y, Liu Q, Shen Y, Li Y, Shao K, Ye B, Shen Y, Zhou Y, Wu D

Source‎: Platelets. 2022 3;33(7):1024-1030.

مفهرسة‎: PubMed 35040375

DOI‎: 10.1080/09537104.2022.2026910

https://pubmed.ncbi.nlm.nih.gov/35040375/ (يفتح نافذة جديدة)

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. (يفتح نافذة جديدة)

Giagounidis A, Mufti GJ, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Hu K, Woodard P, Yang AS, Kantarjian HM.

Source‎: Cancer 2014;120(12):1838-46.

مفهرسة‎: PubMed 24706489

DOI‎: 10.1002/cncr.28663

https://www.ncbi.nlm.nih.gov/pubmed/24706489 (يفتح نافذة جديدة)

A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. (يفتح نافذة جديدة)

Greenberg PL, Garcia-Manero G, Moore M, Damon L, Roboz G, Hu K, Yang AS, Franklin J.

Source‎: Leuk Lymphoma 2013;54(2):321-8.

مفهرسة‎: PubMed 22906162

DOI‎: 10.3109/10428194.2012.713477

https://www.ncbi.nlm.nih.gov/pubmed/22906162 (يفتح نافذة جديدة)

Thrombopoietin-receptor agonists in haematological disorders: the Danish experience. (يفتح نافذة جديدة)

Gudbrandsdottir S, Frederiksen H, Hasselbalch H.

Source‎: Platelets 2012;23(6):423-9.

مفهرسة‎: PubMed 22185370

DOI‎: 10.3109/09537104.2011.634931

https://www.ncbi.nlm.nih.gov/pubmed/22185370 (يفتح نافذة جديدة)

Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial. (يفتح نافذة جديدة)

Han TT, Xu LP, Liu DH, Liu KY, Wang FR, Wang Y, Yan CH, Chen YH, Sun YQ, Ji Y, Wang JZ, Zhang XH, Huang XJ.

Source‎: Ann Hematol 2015;94(1):117-28.

مفهرسة‎: PubMed 25069650

DOI‎: 10.1007/s00277-014-2158-1

https://www.ncbi.nlm.nih.gov/pubmed/25069650 (يفتح نافذة جديدة)

The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma. (يفتح نافذة جديدة)

Jeong JY, Levine MS, Abayasekara N, Berliner N, Laubach J, Vanasse GJ.

Source‎: J Hematol Oncol 2015;8:37.

مفهرسة‎: PubMed 25886818

DOI‎: 10.1186/s13045-015-0136-2

https://www.ncbi.nlm.nih.gov/pubmed/25886818 (يفتح نافذة جديدة)

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. (يفتح نافذة جديدة)

Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P, Shammo J, Siegel R, Hu K, Franklin J, Berger DP.

Source‎: J Clin Oncol 2010;28(3):437-44.

مفهرسة‎: PubMed 20008626

DOI‎: 10.1200/JCO.2009.24.7999

https://www.ncbi.nlm.nih.gov/pubmed/20008626 (يفتح نافذة جديدة)

The use of simple patient blood management strategies as an alternative to platelet and red cell transfusion in autologous stem cell transplant. (يفتح نافذة جديدة)

Locantore-Ford P, Grant SJ, Keck G.

Source‎: Blood 2013;122(21):2140.

https://www.bloodjournal.org/content/122/21/2140 (يفتح نافذة جديدة)

The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply. (يفتح نافذة جديدة)

Loo M, Beguin Y.

Source‎: Blood 1999;93(10):3286-93.

مفهرسة‎: PubMed 10233880

https://www.ncbi.nlm.nih.gov/pubmed/10233880 (يفتح نافذة جديدة)

A single center experience with romiplostim for the management of chemotherapy-induced thrombocytopenia. (يفتح نافذة جديدة)

Miao J, Leblebjian H, Scullion B, Parnes A

Source‎: Am J Hematol 2018;93(4):E86-E88.

مفهرسة‎: PubMed 29274130

DOI‎: 10.1002/ajh.25022

https://www.ncbi.nlm.nih.gov/pubmed/29274130 (يفتح نافذة جديدة)

Pharmacological therapies to minimise platelet transfusion. (يفتح نافذة جديدة)

Norfolk DR, Seghatchian J.

Source‎: Transfus Sci 2000;22(3):149-53.

مفهرسة‎: PubMed 10831916

https://www.ncbi.nlm.nih.gov/pubmed/10831916 (يفتح نافذة جديدة)

Romiplostim for management of chemotherapy-induced thrombocytopenia. (يفتح نافذة جديدة)

Parameswaran R, Lunning M, Mantha S, Devlin S, Hamilton A, Schwartz G, Soff G.

Source‎: Support Care Cancer 2014;22(5):1217-22.

مفهرسة‎: PubMed 24414994

DOI‎: 10.1007/s00520-013-2074-2

https://www.ncbi.nlm.nih.gov/pubmed/24414994 (يفتح نافذة جديدة)

Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders. (يفتح نافذة جديدة)

Pathak S, Roth M, Verma A, Steidl U.

Source‎: Expert Opin Drug Metab Toxicol 2013;9(12):1667-75.

مفهرسة‎: PubMed 24215532

DOI‎: 10.1517/17425255.2013.858119

https://www.ncbi.nlm.nih.gov/pubmed/24215532 (يفتح نافذة جديدة)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (يفتح نافذة جديدة)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Source‎: Leuk Lymphoma. 2019;60(9):2324-7.

مفهرسة‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (يفتح نافذة جديدة)

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. (يفتح نافذة جديدة)

Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A.

Source‎: Lancet Haematol 2015;2(10):e417-26.

مفهرسة‎: PubMed 26686043

https://www.ncbi.nlm.nih.gov/pubmed/26686043 (يفتح نافذة جديدة)

Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation. (يفتح نافذة جديدة)

Poon LM, Di Stasi A, Popat U, Champlin RE, Ciurea SO.

Source‎: Am J Blood Res 2013;3(3):260-4.

مفهرسة‎: PubMed 23997988

https://www.ncbi.nlm.nih.gov/pubmed/23997988 (يفتح نافذة جديدة)

Safety and efficacy of eltrombopag in post-hematopoietic stem cell transplantation (HSCT) thrombocytopenia. (يفتح نافذة جديدة)

Raut SS, Shah SA, Sharanangat VV, Shah KM, Patel KA, Anand AS, Talati SS, Panchal HP, Patel AA, Parikh SK, Shukla SN.

Source‎: Indian J Hematol Blood Transfus 2015;31(4):413-5.

مفهرسة‎: PubMed 26306064

DOI‎: 10.1007/s12288-014-0491-0

https://www.ncbi.nlm.nih.gov/pubmed/26306064 (يفتح نافذة جديدة)

Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. (يفتح نافذة جديدة)

Reese JA, Li X, Hauben M, Aster RH, Bougie DW, Curtis BR, George JN, Vesely SK.

Source‎: Blood 2010;116(12):2127-33.

مفهرسة‎: PubMed 20530792

DOI‎: 10.1182/blood-2010-03-276691

https://www.ncbi.nlm.nih.gov/pubmed/20530792 (يفتح نافذة جديدة)

Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. (يفتح نافذة جديدة)

Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U.

Source‎: Blood 2012;120(2):386-94.

مفهرسة‎: PubMed 22627766

DOI‎: 10.1182/blood-2011-12-399667

https://www.ncbi.nlm.nih.gov/pubmed/22627766 (يفتح نافذة جديدة)

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. (يفتح نافذة جديدة)

Sekeres MA, Kantarjian H, Fenaux P, Becker P, Boruchov A, Guerci-Bresler A, Hu K, Franklin J, Wang YM, Berger D.

Source‎: Cancer 2011;117(5):992-1000.

مفهرسة‎: PubMed 20945323

DOI‎: 10.1002/cncr.25545

https://www.ncbi.nlm.nih.gov/pubmed/20945323 (يفتح نافذة جديدة)

Romiplostim treatment of chemotherapy-induced thrombocytopenia. (يفتح نافذة جديدة)

Soff GA, Miao Y, Bendheim G, Batista J, Mones JV, Parameswaran R, Wilkins CR, Devlin SM, Abou-Alfa GK, Cercek A, Kemeny NE, Sarasohn DM, Mantha S

Source‎: J Clin Oncol 2019;37(31):2892-8.

مفهرسة‎: PubMed 31545663

DOI‎: 10.1200/JCO.18.01931

https://www.ncbi.nlm.nih.gov/pubmed/31545663 (يفتح نافذة جديدة)

Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. (يفتح نافذة جديدة)

Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, Kabrna E, Geissler K, Jilma B.

Source‎: Blood 2000;95(9):2983-9.

مفهرسة‎: PubMed 10779449

https://www.ncbi.nlm.nih.gov/pubmed/10779449 (يفتح نافذة جديدة)

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. (يفتح نافذة جديدة)

Svensson T, Chowdhury O, Garelius H, Lorenz F, Saft L, Jacobsen SE, Hellström-Lindberg E, Cherif H.

Source‎: Eur J Haematol 2014;93(5):439-45.

مفهرسة‎: PubMed 24853277

DOI‎: 10.1111/ejh.12383

https://www.ncbi.nlm.nih.gov/pubmed/24853277 (يفتح نافذة جديدة)

Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation. (يفتح نافذة جديدة)

Tanaka T, Inamoto Y, Yamashita T, Fuji S, Okinaka K, Kurosawa S, Kim SW, Tanosaki R, Fukuda T.

Source‎: Biol Blood Marrow Transplant 2016;22(5):919-24.

مفهرسة‎: PubMed 26785333

DOI‎: 10.1016/j.bbmt.2016.01.018

https://www.ncbi.nlm.nih.gov/pubmed/26785333 (يفتح نافذة جديدة)

Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. (يفتح نافذة جديدة)

Tsimberidou AM, Giles FJ, Khouri I, Bueso-Ramos C, Pilat S, Thomas DA, Cortes J, Kurzrock R.

Source‎: Ann Oncol 2005;16(1):139-45.

مفهرسة‎: PubMed 15598951

DOI‎: 10.1093/annonc/mdi007

https://www.ncbi.nlm.nih.gov/pubmed/15598951 (يفتح نافذة جديدة)

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. (يفتح نافذة جديدة)

Wang ES, Lyons RM, Larson RA, Gandhi S, Liu D, Matei C, Scott B, Hu K, Yang AS.

Source‎: J Hematol Oncol 2012;5:71.

مفهرسة‎: PubMed 23190430

DOI‎: 10.1186/1756-8722-5-71

https://www.ncbi.nlm.nih.gov/pubmed/23190430 (يفتح نافذة جديدة)

Romiplostim for chemotherapy-induced thrombocytopenia: efficacy and safety of extended use. (يفتح نافذة جديدة)

Wilkins CR, Ortiz J, Gilbert LJ, Yin S, Mones JV, Parameswaran R, Mantha S, Soff GA

Source‎: Res Pract Thromb Haemost. 2022;6(3):e12701.

مفهرسة‎: PubMed 35582038

DOI‎: 10.1002/rth2.12701

https://pubmed.ncbi.nlm.nih.gov/35582038/ (يفتح نافذة جديدة)

Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. (يفتح نافذة جديدة)

Will B, Kawahara M, Luciano JP, Bruns I, Parekh S, Erickson-Miller CL, Aivado MA, Verma A, Steidl U.

Source‎: Blood 2009;114(18):3899-908.

مفهرسة‎: PubMed 19710504

DOI‎: 10.1182/blood-2009-04-219493

https://www.ncbi.nlm.nih.gov/pubmed/19710504 (يفتح نافذة جديدة)